A new approach for immune-cold cancers
Making tumors visible to the immune system.
LurexBio is developing a non-genetic, non-viral recognition engineering platform designed to address an important component of tumor immune evasion in immune-cold cancers.
Different biology. A new possibility.
Immunotherapy has transformed cancer care, but many solid tumors remain invisible to the immune system. That is not a problem of immune strength. It is a problem of recognition.
The immune system isn’t weak. In many solid tumors, it’s blind.
Recognition first. Amplification second.
Non-viral
No viral vector delivery
Non-genetic
No edits to the tumor genome
Modular
Adaptable across tumor types
Programmable
Designed to evolve with the science
Immune evasion limits options for many patients.
Many solid tumors, including MSS colorectal cancer and pancreatic ductal adenocarcinoma, can evade immune recognition, limiting the effectiveness of current treatments.
Tumors use multiple mechanisms to avoid detection
Current treatment options remain limited
Addressing recognition may unlock new possibilities
Recognition engineering at the tumor surface.
Our modular platform is designed to install a synthetic immune flag on tumor surfaces, with the goal of enhancing immune recognition and creating new opportunities for therapeutic benefit.
Core platform layers
Provisional patent applications
Inventive embodiments
Initial indications
One platform. Four programmable layers.
NeoTag
Signal
Designed to install a recognizable immune marker on the tumor cell surface, drawing on signals the immune system already knows.
Learn more
Atraxis
Delivery
Vesicle-mediated membrane fusion designed to deliver the signal to the tumor surface without genetic modification or viral vectors.
Learn more
AegisCore
Control
Programmable safety and activation logic designed to govern when, where, and how the platform acts.
Learn more
StratIQ
Decision
The governing decision framework designed to coordinate every layer as a single, context-aware system.
Learn more
NeoTag
Signal
Designed to install a recognizable immune marker on the tumor cell surface, drawing on signals the immune system already knows.
Learn more Atraxis
Delivery
Vesicle-mediated membrane fusion designed to deliver the signal to the tumor surface without genetic modification or viral vectors.
Learn more AegisCore
Control
Programmable safety and activation logic designed to govern when, where, and how the platform acts.
Learn more StratIQ
Decision
The governing decision framework designed to coordinate every layer as a single, context-aware system.
Learn more Focused on high unmet need in immune-cold cancers.
Where we are starting
MSS colorectal cancer
Microsatellite-stable (MSS) disease
A large patient population
Limited options in the metastatic setting
Typically immune-cold
Pancreatic cancer (PDAC)
Pancreatic ductal adenocarcinoma
An aggressive disease
High unmet need and poor outcomes
Among the most immune-cold tumors
Current stage
Preclinical
Join us in advancing a new approach.
We welcome conversations with investors, potential partners, and talented individuals who share our vision.